Breeze Meds vs Hers: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

Breeze Meds and Hers are tied at 7.3/10. Choose Breeze Meds for users who want a straightforward compounded glp-1 program wi. Choose Hers for women who want brand-name wegovy (injection or pill) at $149.

A side-by-side comparison of Breeze Meds and Hers covering pricing, scores, medication types, insurance, and more to help you decide.

Breeze Meds

#34 of 48

7.3/10

Compounded GLP-1 provider focused on fast shipping and a no-fuss enrollment process.

Visit Breeze Meds

Hers

#35 of 48

7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.

Visit Hers

Feature	Breeze Meds	Hers
Our Score	7.3/10	7.3/10
Starting Price	$199/mo	$199/mo
Medication Type	Compounded	Both
Insurance Accepted	No	No
Best For	Users who want a straightforward compounded GLP-1 program with fast shipping	Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand
Ranking	#34	#35

Pros & Cons Compared

Breeze Meds

Pros

+No subscription required — order on demand without recurring billing commitments
+Three formulation options: injectable semaglutide, oral semaglutide tablet, and oral tirzepatide tablet
+FSA/HSA eligible for those with health savings accounts
+Discreet packaging on all shipments

Cons

−Very limited independent reviews and unclear company structure — legitimacy is hard to verify
−Oral options at $299-399/mo are significantly more expensive than injectable alternatives
−Not available in all 50 states — varies by provider licensure in your state

Hers

Pros

+2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
+Zepbound access via the Lilly/Hims-Hers partnership announced 2026
+Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
+Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services

Cons

−Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
−Generic support experience — large patient volume means less personalized attention
−Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
−Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value

Our Verdict

Breeze Meds and Hers are closely matched with identical scores of 7.3/10. Hers offers both brand-name and compounded medications, giving you more flexibility. Choose Breeze Meds if you want: users who want a straightforward compounded glp-1 program with fast shipping. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Breeze Meds nor Hers feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review